Form 4: Organogenesis Holdings Inc. Insiders Reduce Holdings Through Stock Repurchase

Multiple insiders of Organogenesis Holdings Inc. sold shares back to the company through a stock repurchase agreement, reducing their holdings.

Summary

• This SEC Form 4 filing details the changes in beneficial ownership of Organogenesis Holdings Inc. stock by several insiders.
• The transactions occurred on November 12, 2024, and involved the repurchase of Class A Common Stock by the company from various entities and individuals.
• The price per share for the repurchase was $3.1597, based on the 10-day trailing volume weighted average price.
• The filing shows a reduction in the number of shares held by several insiders, including Albert Erani, RED Holdings, LLC, Alan A. Ades, Alan Ades 2014 GRAT, and Glenn H. Nussdorf.
• The total number of shares sold back to the company was 7,171,731.
• The insiders are part of a group that has a Controlling Stockholders' Agreement with Organogenesis, granting them nomination rights for four directors.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document primarily reports a stock repurchase transaction, which is a common corporate action. The reduction in insider holdings could be viewed with slight negativity, but it is part of a pre-arranged agreement.

Negatives

• The stock repurchase resulted in a reduction of shareholdings by several key insiders.

Risks

• The reduction in insider holdings could be perceived negatively by the market.
• The stock repurchase may indicate a lack of confidence in the company's future prospects by some insiders.

Industry Context

Stock repurchases are a common practice for companies to return capital to shareholders or to manage their capital structure. Insider selling can sometimes be viewed negatively by the market, but in this case, it is part of a pre-arranged stock repurchase agreement.

Comparison to Industry Standards

• Stock repurchases are a common capital management tool used by public companies, including those in the biotechnology and healthcare sectors like Organogenesis.
• Companies such as Integra LifeSciences and ACell, which are also in the regenerative medicine space, have also engaged in stock repurchases as part of their financial strategies.
• The price of $3.1597 per share is based on a 10-day trailing volume weighted average price, which is a standard method for determining fair value in such transactions.
• The level of insider selling is not unusual, but the market will be watching to see if this is a one-off event or part of a larger trend.

Stakeholder Impact

• Shareholders may react to the reduction in insider holdings, potentially impacting the stock price.
• The stock repurchase reduces the number of outstanding shares, which could have a minor positive impact on earnings per share.

Key Dates

Keywords

Organogenesis Holdings Inc., insider trading, stock repurchase, SEC Form 4, beneficial ownership, Class A Common Stock, controlling stockholders agreement